---
schema_version: "secwatch.filing_event.v1"
accession: "0001698530-25-000006"
form_type: "8-K/A"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T14:44:44.634012+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exicure acquires GPCR Therapeutics USA and signs license/collaboration agreement

## Summary
- Acquired all outstanding equity of GPCR Therapeutics USA from GPCR Therapeutics Inc.; deal closed concurrently with execution.
- Entered License and Collaboration Agreement to develop and commercialize GPCR's technologies and patents.
- Must make milestone payments tied to clinical trial, regulatory, and sales milestones; royalty of at least 10% of net sales.
- Corrected press release filed as an amendment to the January 22, 2025 8-K.

## SEC filing metadata
- accession: 0001698530-25-000006
- form_type: 8-K/A
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000169853025000006/0001698530-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000169853025000006/xcur-20250123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001698530-25-000006
- JSON: https://secwatch.observer/filing/0001698530-25-000006.json
- Plain text: https://secwatch.observer/filing/0001698530-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.